sodium iodide-131 is administrated for treatment of hyperthyroidism and thyroid cancer. iodine-131 has multiple routs of excretion (urine, saliva, sweat, milk, feces, exhalation) from the body. patients receiving sodium iodide-131 therapy exposes other persons and the environment to unwanted radiation and contamination. the major source of radiation dose from administration of iodine-131 is ext...

Objective: Resistance of metastatic lymph nodes (LNs) to high dose I-131 therapy is associated with high morbidity in patients with differentiated thyroid cancer. We evaluated the role of F-18 FDG PET/CT in the prediction of resistance to high dose I-131 therapy in patients with papillary thyroid cancer. Methods: The subjects were 307 patients who underwent total or near total thyroidectomy fol...

Abstract Introduction Around 50%-70% of all women, at any moment their lives, will undergo pelvic surgery such as abdominal and vaginal hysterectomies, laparoscopic or robotic-assisted exploratory laparotomies for multiple reasons. These reasons include; endometriosis, chronic pain, adhesions secondary to inflammatory disease, infected perforated IUDs, previous surgeries, abscesses cysts, perit...

UNLABELLED Arsenic trioxide has in vitro and in vivo radiosensitizing properties. We hypothesized that arsenic trioxide would enhance the efficacy of the targeted radiotherapeutic agent (131)I-metaiodobenzylguanidine ((131)I-MIBG) and tested the combination in a phase II clinical trial. METHODS Patients with recurrent or refractory stage 4 neuroblastoma or metastatic paraganglioma/pheochromoc...

O(6)-Substituted guanine derivatives are powerful agents used for tumor cell sensitization by inhibition of the DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT). To provide targeted accumulation of MGMT inhibitors in tumor tissue as well as tools for in vivo imaging, we synthesized iodinated C(8)-alkyl-linked glucose conjugates of 2-amino-6-(5-iodothenyl)-9H-purine (O(6)-(5-iod...

BACKGROUND Little is known about the whole body oxidative stress burden following radioactive iodine ((131)I) therapy of thyroid diseases. METHODS We studied 17 patients with benign nodular goiter treated with (131)I therapy. The targeted thyroid dose was 50 Gy in 11 patients pretreated with 0.1 mg of recombinant human TSH (rhTSH). In 6 patients, the applied thyroid dose was 100 Gy without rh...